Penalized Bayesian methods for product ranking using both positive and negative references.

IF 1.2 4区 医学 Q4 PHARMACOLOGY & PHARMACY
Clement Laloux, Bruno Boulanger, Philippe Bastien, Bradley P Carlin, Arnaud Monseur, Carole Guillou, Daiane Garcia Mercurio, Hussein Jouni
{"title":"Penalized Bayesian methods for product ranking using both positive and negative references.","authors":"Clement Laloux, Bruno Boulanger, Philippe Bastien, Bradley P Carlin, Arnaud Monseur, Carole Guillou, Daiane Garcia Mercurio, Hussein Jouni","doi":"10.1080/10543406.2025.2489287","DOIUrl":null,"url":null,"abstract":"<p><p>Product ranking according to pre-specified criteria is essential for developing new technologies, allowing identification of more preferable candidates for further development. Such ranking often builds on the results of a network meta-analysis, where the relative or absolute performances of the various products are synthesized across multiple clinical studies, each of which considered only a subset of the products. Ranking involving both a negative and a positive reference enables the scientist to directly compare tested products against known benchmarks. Here, more preferable candidates are those products that approach the positive reference while remaining distant from the negative reference. We provide a new metric to quantify this multivariate distance following Bayesian meta-analysis. Our method does not simply rely on point estimates to perform the comparisons, but also accounts for their uncertainties via their posterior distributions. For each product, posterior probabilities of being comparable to the positive reference are computed, and subsequently penalized by the posterior probability of performing worse than the negative reference. Each product is then compared to a hypothetical product about which we have no knowledge, as captured by a uniform distribution. The result is a prospective metric that is directly interpretable as the improvement of any product beyond this state of ignorance. We illustrate our approach using a case study, in which the goal is to rank 16 antiperspirant products. Here, the FDA-recommended summary statistic (a measure of the relative sweat reduction between each product and no treatment) intrinsically features both positive and negative references. We then offer a brief simulation study to check our metric's performance in less complex, idealized settings where the true ranking is known. Our results indicate that our Bayesian approach is a novel and useful addition to the statistical ranking toolkit.</p>","PeriodicalId":54870,"journal":{"name":"Journal of Biopharmaceutical Statistics","volume":" ","pages":"1-17"},"PeriodicalIF":1.2000,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Biopharmaceutical Statistics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10543406.2025.2489287","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Product ranking according to pre-specified criteria is essential for developing new technologies, allowing identification of more preferable candidates for further development. Such ranking often builds on the results of a network meta-analysis, where the relative or absolute performances of the various products are synthesized across multiple clinical studies, each of which considered only a subset of the products. Ranking involving both a negative and a positive reference enables the scientist to directly compare tested products against known benchmarks. Here, more preferable candidates are those products that approach the positive reference while remaining distant from the negative reference. We provide a new metric to quantify this multivariate distance following Bayesian meta-analysis. Our method does not simply rely on point estimates to perform the comparisons, but also accounts for their uncertainties via their posterior distributions. For each product, posterior probabilities of being comparable to the positive reference are computed, and subsequently penalized by the posterior probability of performing worse than the negative reference. Each product is then compared to a hypothetical product about which we have no knowledge, as captured by a uniform distribution. The result is a prospective metric that is directly interpretable as the improvement of any product beyond this state of ignorance. We illustrate our approach using a case study, in which the goal is to rank 16 antiperspirant products. Here, the FDA-recommended summary statistic (a measure of the relative sweat reduction between each product and no treatment) intrinsically features both positive and negative references. We then offer a brief simulation study to check our metric's performance in less complex, idealized settings where the true ranking is known. Our results indicate that our Bayesian approach is a novel and useful addition to the statistical ranking toolkit.

惩罚贝叶斯方法的产品排名使用正面和负面的参考。
根据预先指定的标准对产品进行排名对于开发新技术至关重要,可以确定更可取的候选产品以进行进一步开发。这种排名通常建立在网络荟萃分析的结果之上,其中各种产品的相对或绝对性能是在多个临床研究中综合的,每个临床研究只考虑产品的一个子集。包括消极和积极参考的排名使科学家能够直接将测试产品与已知基准进行比较。在这里,更可取的候选者是那些接近积极参考而远离消极参考的产品。我们根据贝叶斯元分析提供了一种新的度量来量化这种多变量距离。我们的方法不是简单地依靠点估计来进行比较,而是通过它们的后验分布来解释它们的不确定性。对于每个产品,计算与正面参考相媲美的后验概率,然后通过比负面参考表现更差的后验概率进行惩罚。然后将每个产品与我们不知道的假设产品进行比较,该假设产品由均匀分布捕获。结果是一个前瞻性指标,可以直接解释为任何产品超越这种无知状态的改进。我们用一个案例研究来说明我们的方法,其中的目标是对16种止汗产品进行排名。在这里,fda推荐的汇总统计数据(衡量每种产品与未处理产品之间的相对排汗量)本质上既有积极的参考,也有消极的参考。然后,我们提供了一个简短的模拟研究,以检查我们的指标在不太复杂的理想设置中的性能,其中真实排名是已知的。我们的结果表明,我们的贝叶斯方法是统计排名工具包的一个新颖而有用的补充。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Biopharmaceutical Statistics
Journal of Biopharmaceutical Statistics 医学-统计学与概率论
CiteScore
2.50
自引率
18.20%
发文量
71
审稿时长
6-12 weeks
期刊介绍: The Journal of Biopharmaceutical Statistics, a rapid publication journal, discusses quality applications of statistics in biopharmaceutical research and development. Now publishing six times per year, it includes expositions of statistical methodology with immediate applicability to biopharmaceutical research in the form of full-length and short manuscripts, review articles, selected/invited conference papers, short articles, and letters to the editor. Addressing timely and provocative topics important to the biostatistical profession, the journal covers: Drug, device, and biological research and development; Drug screening and drug design; Assessment of pharmacological activity; Pharmaceutical formulation and scale-up; Preclinical safety assessment; Bioavailability, bioequivalence, and pharmacokinetics; Phase, I, II, and III clinical development including complex innovative designs; Premarket approval assessment of clinical safety; Postmarketing surveillance; Big data and artificial intelligence and applications.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信